paediatric
Results from Novadip phase 1b/2a trial reveal 88% efficacy
January 28, 2025Clinical Research Congenital Pseudoarthritis of the Tibia, Rare Diseases, clinical trials, efficacy, paediatric, rare diseases
Novadip Biosciences, a clinical stage biotechnology company with a specialty in regenerative medicine, has announced the results of its 12-month …
Japan approves AstraZeneca’s Soliris for paediatric patients with gMG
August 24, 2023Medical Communications AstraZeneca, MHLW, Musculo-skeletal disorder, gMG, paediatric, soliris
AstraZeneca has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Soliris (eculizumab) for the extended use …
FDA approves first new ADHD drug in a decade
April 6, 2021Manufacturing and Production ADHD, FDA, paediatric
The FDA have approved the first new drug for the treatment of attention deficit hyperactivity disorder (ADHD) in over a …
Novartis posts 82% remission rate in CAR T paediatric study
December 5, 2016Research and Development, Sales and Marketing CAR T, CAR-T, Novartis, leukaemia, paediatric
Novartis has released the results of its global, paediatric study of the treatment of leukaemia in children and young adults …
FDA approves first therapy for paediatric psoriasis treatment
November 7, 2016Sales and Marketing Amgen, Enbrel, paediatric, psoriasis
Amgen’s Enbrel has been given approval by the FDA for expanded use to treat children with chronic moderate-to-severe plaque psoriasis. …
Shire gets positive opinion from EMA on rare gastrointestinal disease treatment
May 27, 2016Medical Communications, Research and Development, Sales and Marketing CHMP, EMA, Revestive, Shire, gastrointestinal, paediatric, short bowel syndrome, treatment
Shire (LSE: SHP) has announced that it has received a positive opinion from the European Medicines Agency’s (EMA) Committee for …
FDA grants priority review for Amgen leukaemia drug
May 4, 2016Research and Development, Sales and Marketing Amgen, FDA, blincyto, leukaemia, lymphoblastic leukaemia, paediatric
Amgen has announced that the US Food and Drug Administration (FDA) has granted priority review status for the supplemental Biologics …
Bluebird Bio gene therapy posts encouraging results in treatment of rare brain disease
April 21, 2016Medical Communications, Research and Development Bluebird Bio, Phase II, gene therapy, lenti-d, paediatric, phase 2, phase 3, phase III, rare brain disease
Bluebird bio (NASDAQ: BLUE) has announced positive interim data from a Phase II/III trial evaluating their Lenti-D gene therapy in …
Amgen’s drug reduces rates of bleeding in rare childhood disorder
April 21, 2016Research and Development, Sales and Marketing Amgen, blood disorder, children, nplate, paediatric, platelet, rare, romisplostim
Amgen (NASDAQ: AMGN) has announced the results of a Phase III trial, published in The Lancet, which shows that Nplate …
EMA readies paediatric trials network
May 14, 2010Research and Development EMA, EMEA, paediatric, paediatric trials
The European Medicines Agency is about to press the start button on its long-planned network for clinical studies in children. …
FDA to study effects of medication during pregnancy
January 20, 2010Research and Development, Sales and Marketing FDA, paediatric
A new US-based collaborative research programme to study the effects of medication on mothers and their babies has been launched. …
UK children recruited for H1N1 vaccine trials
October 2, 2009Research and Development, Sales and Marketing h1n1, paediatric, vaccines
The UK has commenced a two-week swine flu vaccine trial, a month ahead of its planned programme to vaccinate 11 …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
